Mediwound's nexobrid® highlighted in 45 posters and presentations at the 19th european burns association congress

Yavne, israel, sept. 12, 2022 (globe newswire) -- mediwound ltd. (nasdaq: mdwd) (“mediwound”), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced its successful and meaningful presence at the recently concluded 19th european burns association (eba) congress held in turin, italy on september 7-10, 2022.
MDWD Ratings Summary
MDWD Quant Ranking